114 related articles for article (PubMed ID: 19795097)
1. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis.
Jasinski P; Zwolak P; Terai K; Borja-Cacho D; Dudek AZ
Invest New Drugs; 2011 Feb; 29(1):33-40. PubMed ID: 19795097
[TBL] [Abstract][Full Text] [Related]
2. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.
Jasinski P; Welsh B; Galvez J; Land D; Zwolak P; Ghandi L; Terai K; Dudek AZ
Invest New Drugs; 2008 Jun; 26(3):223-32. PubMed ID: 17957339
[TBL] [Abstract][Full Text] [Related]
3. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
Jasinski P; Zwolak P; Terai K; Dudek AZ
Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
[TBL] [Abstract][Full Text] [Related]
4. MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling.
Jasinski P; Zwolak P; Terai K; Vogel RI; Borja-Cacho D; Dudek AZ
Anticancer Res; 2011 Apr; 31(4):1181-7. PubMed ID: 21508363
[TBL] [Abstract][Full Text] [Related]
5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
6. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
7. ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.
Thamkachy R; Kumar R; Rajasekharan KN; Sengupta S
Mol Cancer; 2016 Mar; 15():22. PubMed ID: 26956619
[TBL] [Abstract][Full Text] [Related]
8. Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.
Ganapathy S; Peng B; Shen L; Yu T; Lafontant J; Li P; Xiong R; Makriyannis A; Chen C
Oncotarget; 2017 May; 8(19):30992-31002. PubMed ID: 28415683
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
10. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
He S; Dibas A; Yorio T; Prasanna G
Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling.
Hu T; Shen H; Huang H; Yang Z; Zhou Y; Zhao G
Anticancer Drugs; 2020 Apr; 31(4):377-384. PubMed ID: 32011362
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641.
Kitatani K; Idkowiak-Baldys J; Hannun YA
J Biol Chem; 2007 Jul; 282(28):20647-56. PubMed ID: 17504762
[TBL] [Abstract][Full Text] [Related]
13. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
Shi M; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2014; 14(2):217-24. PubMed ID: 24467518
[TBL] [Abstract][Full Text] [Related]
18. Disruption of alpha-actinin-integrin interactions at focal adhesions renders osteoblasts susceptible to apoptosis.
Triplett JW; Pavalko FM
Am J Physiol Cell Physiol; 2006 Nov; 291(5):C909-21. PubMed ID: 16807302
[TBL] [Abstract][Full Text] [Related]
19. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T
Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
[TBL] [Abstract][Full Text] [Related]
20. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
